Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.

被引：0
|
作者：
Dong, Pei [1 ]
Wei, Wensu [1 ]
Jiang, Lijuan [1 ]
Zhang, Zhiling [1 ]
Guo, Shengjie [1 ]
Han, Hui [1 ]
Cai, Xiuyu [1 ]
Zhou, Fangjian [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16546
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
  • [22] A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
    Osterman, Chelsea K.
    Rose, Tracy L.
    KIDNEY CANCER, 2020, 4 (01) : 15 - 27
  • [23] Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.
    Kilari, Deepak
    Szabo, Aniko
    Ghatalia, Pooja
    Rose, Tracy L.
    Weise, Nicole
    Tucker, Matthew D.
    Nelson, Ariel Ann
    Dong, Huaying
    Hester, Danubia
    Acharya, Luna
    Jain, Rohit K.
    Maughan, Benjamin L.
    Alva, Ajjai Shivaram
    Tripathi, Abhishek
    Basu, Arnab
    Koshkin, Vadim S.
    Emamekhoo, Hamid
    Davis, Nancy B.
    Desai, Arpita
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
    Hu, Xu
    Zhao, Fengnian
    Chen, Yuntian
    Zhao, Junjie
    Shi, Yifu
    Tang, Yanfeng
    Wang, Yongquan
    Zhang, Xingming
    Liang, Jiayu
    Zhao, Jinge
    Chen, Junru
    Wei, Qiang
    Li, Xiang
    Liu, Jiyan
    Chen, Ni
    Shen, Pengfei
    Yao, Jin
    Sun, Guangxi
    Liu, Zhenhua
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 544 - 544
  • [25] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [26] Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review
    Wang, Lei
    Huang, Yingyu
    Sun, Xin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
    Tannir, Nizar M.
    Plimack, Elizabeth
    Chaan Ng
    Tamboli, Pheroze
    Bekele, Nebiyou B.
    Xiao, Lianchun
    Smith, Lisa
    Lim, Zita
    Pagliaro, Lance
    Araujo, John
    Aparicio, Ana
    Matin, Surena
    Wood, Christopher G.
    Jonasch, Eric
    EUROPEAN UROLOGY, 2012, 62 (06) : 1013 - 1019
  • [28] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [29] Prognostic and predictive plasma cytokines and angiogenic factors (CAF) in patients (pts) with advanced non-clear cell renal cell carcinoma treated with first-line sunitinib or everolimus: Results from the ESPN trial.
    Msaouel, Pavlos
    Zurita, Amado J.
    Huang, Shixia
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.
    Vogelzang, Nicholas J.
    McFarlane, Joshua Jemison
    Kochenderfer, Mark D.
    Molina, Ana M.
    Arrowsmith, Edward
    Bauer, Todd Michael
    Hauke, Ralph J.
    Jain, Rohit
    Somer, Bradley G.
    Lam, Elaine Tat
    Doshi, Gurjyot K.
    Gunuganti, Vijay
    Zhang, Joshua
    Zhao, Huanyu
    Johansen, Jennifer
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345